Overview

A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)

Status:
Active, not recruiting

Trial end date:
2020-11-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, single arm, open label phase II study in treatment-naïve for advanced stage of the disease and immunotherapy-naïve patients with advanced non-squamous NSCLC and with < 50% of tumor cells expressing PD-L1 by immunohistochemical (IHC) staining.

Phase:

Phase 2

Details

Lead Sponsor:

Transgene

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Nivolumab